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Blocked synthesis of A and B determinants in human epithelial and endoder- 
mal tumors have been described based on immunochemical (1, 2), immunohisto- 
logical (3, 4), and enzymatic (5) studies. The change of Lewis blood group hapten 
and accumulation of LeX-like antigen in some adenocarcinoma were described 
(6).  Immunohistological studies indicated that blood group determinants ap- 
peared and disappeared in a certain order during ontogenetic development (7), 
that the H determinant was demonstrated to be a marker of cellular differentia- 
tion (8), and that the development of i to I antigen was shown to be associated 
with postnatal change of erythrocytes (9). The association of I and i antigen with 
tumor tissue (10) and with carcinoembryonic antigen (11) has been described. 
All these findings suggest that a genetic or epigenetic program, for synthesiz- 
ing blood group determinants and their carrier carbohydrate chains, develops 
step-by-step during the process of ontegenesis, and that the program of synthesis 
is blocked or modified in the process of oncogenesis. This paper is to provide new 
experimental evidence to support the following general concepts: (a) ontogenesis 
of a carbohydrate chain occurs as a step-by-step elongation and arborization of a 
complex carbohydrate chain,  as for example that of A c and H3 variants,  (b) 
blocking of the elongation and arborization of a carbohydrate chain occurs dur- 
ing oncogenesis as a result of a blocked ontogenic program. 
Materials and Methods 
A a,  A h,  A ",  A d,  H,,  H2,  H3,  and  H4  glycolipids  were  prepared  from  human  erythrocytes, 
according to  the  method  previously described  (12,  I3).  The structures of each glycolipid were 
determined,  as  seen  in  Table  I,  by  enzymatic  degradation,  methylation  analysis,  and  mass 
spectrometry, as previously described. A ~ and I-L glycolipids were still impure and their structures 
have not been determined. A ~' and H3 glycolipids were identified as ceramide dodeca and decasac- 
charides, respectively. They have two "type 2" chains which are branched at B-galactosyl residue 
of "paragloboside" by fl(1--*3)  and /~(1-.6) linkages (13).  Paragloboside and globoside were pre- 
pared from human erythrocytes and from a  major ganglioside of erythrocytes (14). 
Since blood group glycolipids were minor membrane components and only a  small amount of 
fetal and newborn erythrocytes and tissues were available, the change of blood group glycolipids 
in fetal and newborn erythrocytes were studied by the following two methods: (a) A glycolipids 
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TABLE  I 
Structures of Blood Group H and A Glycolipid Variants 
645 
H glycolipid 
H,:  L-a-Fucl--*  2BGall--*4BGlcNAcl  ~3~Gall  ~4BGlc  ~ceramide 
H2:  L-  aFucl~2~Gall--*4~GlcNAcl--*3BGall--*4GlcNAcl-*3BGall ~4Glc--*ceramide 
H3:  See Fig. 1. 
H4:  Similar to H3 but additional branching, structure not yet determined 
A glycolipid 
A~:  a-GalNAcl~ 
a.L.FuclV32  flGall--*4BGlcNAcl-*3~Gall-~4BGlc-*ceramide 
Ab:  a-GalNAcl~ 
a_L.Fucl  V32 ~Gall  ~4BGlcNAcl-*3BGall--*4BGlcNAcl-*3BGall--*4BGlc  ~ceramide 
A":  ~-GalNAclx. 
/:flGall--*4BGlcNAcl~ 
a-L-Fucl  ~BGall~4BGlcNAcl~3BGall~4BGlc~ceramide 
a-GalNAc~  / 
a'L-Fucl  V32BGall--~4"GlcNAcl  / 
Ad:  Similar to A" but additional branching, the structure not yet determined. 
were  studied  by cell  surface  labeling  with  galactose  oxidase  and  tritiated  borohydride  (15), 
followed by preparation  of membranes (15), extraction,  and preparation of long-chain neutral 
glycolipids (see below).  (b) H  glycolipids and their degradation products were studied through 
reactions of erythrocytes and glycolipids fraction of tissues with antibodies directed against the H3 
glycolipid and its degradation products (structures 2, 3, and 4, see Fig. 1). 
Cell surface labeling was carried out wish  a  higher concentration  of galactose oxidase and 
tritiated borohydride than that previously described, i.e., 30 U of galactose oxidase (Kabi, Lind- 
hagensgaten 133, Stockholm, Sweden) which was added to 0.5 ml of packed erythrocytes and three 
times addition of each 5 mCi of tritiated borohydride. The long-chain neutral glycolipid fraction, 
containing blood group glycolipids, was prepared from the "upper layer" of Folch's extracts of the 
surface-labeled erythrocytes through  DEAE-Sephadex  chromatography  (16). The fraction was 646  BLOOD  GROUP  CARBOHYDRATE  CHAINS  IN ONTOGENESIS 
i 
L-a-Fuc 1~213-Gal  I~4'I~-GIcNAcl  ",,~ 
,~ ~,~11 ~4  fJ- GIcNAc  1-- 3 ~ Gal 1 ~4/3-GIc~Cerarnide, 
;  61  ; 
be-Fuc l~2f}-Gal  1~4 6-GIcNAcl""  i  i(structure  4)  , 
,, 
i(structure  3)  .,, 
;(structure  2)  _,, 
IStructure  1)_ 
Fro.  1.  Structure of H3 glycolipid and its degradation products to which antibodies were 
directed. 
analyzed through thin-layer chromatography on Silica gel G plate after the addition of standard A 
variants (A  a, A b, A t, A"), and the radioactivity of each band was counted. The H3 glycolipid was 
degraded  step-by-step  with  purified  a-L-fucosidase  (12,  13), B-galactosidase,  and  /]-N-acetyl- 
hexosaminidase  (17). Paragloboside  was prepared  from  sialylparagloboside  of human  erythro- 
cytes  (14)  and  was  further  degraded  into  /~-N-acetylglucosaminyl(1--*3)B-galactosyl(1-~4)- 
glucosylceramide  (structure  4,  Fig.  1)  by  fl-galactosidase.  These  glycolipids  were  purified 
through thin-layer chromatography.  The purified glycolipids were complexed with bovine serum 
albumin (BSA)  1 and immunized rabbits with a  complete Freund's adjuvant  (18). Antisera were 
purified  by  BSA-Sepharose  column  to  eliminate  anti-BSA.  Details  of the  procedure  and  the 
properties  of antibodies  will be  described  elsewhere.  Glycolipids of human  gastric  and  colon 
cancer, and those of normal mucosa tissue, were extracted directly by chloroform-methanol (2:1) 
and purified through  acetylation procedure  (19). In some cases,  tissues were first homogenized 
with water in an "Omnimixer" (Ivan Sorval Inc., Norwalk, Conn.) followed by addition of an equal 
vol of 2 M perchloric acid, stirred for 30 min. The mixture was centrifuged to separate perchloric 
acid  soluble  fraction  and  insoluble  cell residue. 2 The  residue  was  extracted  with  chloroform- 
methanol (2:1), and the neutral glycolipid fraction was prepared by acetylation followed by analy- 
sis of glycolipids through thin-layer chromatography (19). The reactivity of individual glycotipids 
and glycoproteins to anti-glycolipid antisera was determined by complement fixation performed 
on a microtiter plate (20) and on an Ochterlong double diffusion agarose plate. The reactivity of 
an adult, newborn fetal erythrocytes with respective antiserum was determined by hemagglutina- 
tion on a  microtiter plate with 1% erythrocytes and by the capability of erythrocytes absorbing 
anti-glycolipid  antibodies.  The  absorbing  capability  of  erythrocytes  was  determined  by  l0  s 
erythrocytes incubated with 50 t~l of an anti-glycolipid antibody which has a  titer of 1:128. The 
erythrocyte suspension, which was incubated with antibody, was centrifuged, and the activity of 
the supernate was titrated on a microtiter plate. 
Results 
The ratios of the surface-labeled activities,  newborn to adult erythrocytes of 
each A variant (A  a, A b, A ~', and Ad), are shown in Table II. Activities of each A 
variant of newborn erythrocytes are expressed as percent of adult erythrocytes. 
The labels of A c and A d variants in fetal erythrocytes were significantly lower 
than those of adult erythrocytes. A similar experiment cannot be carried out for 
H  determinants because they were not quantitatively  labeled. ~ Alternatively, 
Abbreviation used in this paper: BSA, bovine serum albumin. 
The insoluble residue contained essentially all neutral glycolipids except those containing a 
long-carbohydrate chain; the perchloric acid soluble fraction contained glycoprotein, gangliosides, 
and some long-chain glycolipids (Watanabe and Hakomori; unpublished observation). The proce- 
dure was used for simultaneous extraction and fractionation of glycoprotein and glycolipid from a 
small amount of surgical specimen. 
3 The subterminal galactosyl residue of ~-L-Fucl---~2flGal  can be oxidized by galactose oxidase 
and hence can be labeled by the procedure as described. The reaction was, however, not stoichio- 
metric (Matsubara  and Hakomori; unpublished observation). KIYOHIRO  WATANABE  AND  SEN=ITIROH  HAKOMORI 
TABLE  II 
Surface-Labeled Activities of Blood Group A Glycolipids Variant: 
Percent of  Activity of Newborn Erythrocytes to that of Adult 
Erythrocytes 
647 
Percent activity of newborn erythrocytes to adult 
erythrocytes 
A a  A b  A ~  A d 
Experiment 1  95  65  24  20 
Experiment 2  84  92  45  30 
Experiment 3  110  96  46  35 
A erythrocytes of adult and newborn were surface labeled by galactose oxidase 
and tritiated borohydride (15),  membranes were isolated, glycolipid fractions 
were prepared by DEAE-Sephadex chromatography,  and the nonradioactive 
standard  A variants glycolipids were added,  and A a, A b, A% and A n fractions 
were  separated  on  thin-layer  chromatography  (12,  13). Activities  of each 
variant  obtained  from  newborn  erythrocytes  were  compared  with  those  of 
adult erythrocytes. Values were expressed as percent of adult erythrocytes. 
TABLE  III 
Inhibition of Anti-H3-Dependent Hemagglutination by H1, HE, and H3 Glycolipid 
HI glycolipid 
Hz glycolipid 
H3 glycolipid 
Not inhibited by 25 txg/50/~l, partially inhibited by 50 p.g/50  ill 
Not inhibited  by 25 ~tg/50/~I,  partially  inhibited  by 50/~g/50/~I 
Inhibited  completely by 12 ~g/50 pl 
Inhibited partially  by 3 pg/50/~l 
Determined by three hemagglutination  doses of anti-Hs glycolipid rabbit  antisera  (purified by 
BSA-column) and in the presence of two times weight of cholesterol and lecithin. 
the reactivities of erythrocytes  to various antibodies, which are directed against 
H3 and its degradation products, were compared. 
The antibody that was directed against whole H3 glycolipid (structure 1) did 
not strongly cross-react to H1 and H2 structures (see Table III). This indicates 
that the antibody recognizes a whole branched structure. The antibody that was 
directed  against  H3  strongly reacted  to  adult  human  erythrocytes, weakly 
reacted to cord erythrocytes, and did not react at all to fetal erythrocytes (Fig. 
2 A). The higher reactivity of adult erythrocytes to anti-H3 glycolipid has been 
further confirmed through an absorption experiment, i.e., adult erythrocytes 
absorb about eight times the quantity of anti-H3 antibody than newborn eryth- 
rocytes absorb.  106 adult erythrocytes absorb almost all of the anti-H3  activity 
which was present in 50 tL1 of antisera (titer 1:128), whereas the supernate of  the 
same amount of antiserum, which was incubated with the same number of 
newborn erythrocytes, contained the anti-H3 activity with a titer of 1:32 to 1:64. 
No diminished activity in the supernate was observed when fetal erythrocytes 
were incubated with the anti-H3 antiserum. 
The difference in reaction to an anti-H3 antibody between adult and fetal 
erythrocytes became greater a~er trypsin treatment of erythrocytes, i.e., en- 
hanced reaction of adult erythrocytes through trypsin treatment was observed, 
no increase in reaction of fetal erythrocytes at'cer trypsin treatment, and only a 
slight increase of cord erythrocytes (see Fig. 2 A). The agglutinability of both 648  BLOOD  GROUP  CARBOHYDRATE  CHAINS  IN  ONTOGENESIS 
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FIG.  2.  Agglutinability  of adult,  cord (newborn),  and fetal erythrocytes determined  with 
anti-structure  1 (intact H:~), anti-structure 2, anti-structure 3, and anti-structure 4 antibod- 
ies. Agglutinabilities were determined on microtiter plates with 1% erythrocytes and were 
expressed  by  reciprocals  of  the  highest  dilution  of  antibody  that  could  cause  obvious 
hemagglutination.  The values are the mean of 10 cases. A: adult erythrocytes, C: umbilical 
cord  erythrocytes  (newborn  erythrocytes),  F:  fetal  erythrocytes  obtained  from  abortion 
cases. AT: trypsin-treated adult erythrocytes (0.25%, 37°C 15 rain). CT: trypsin-treated cord 
erythrocytes.  FT:  trypsin-treated  fetal  erythrocytes.  The  upper  panel  (A)  is the  results 
determined  at 4°C; the lower panel  (B) is the results determined  at 37°C. 
fetal  and  adult  cells  through  anti-H:~  antibodies  was  not  thermosensitive  as 
compared to the  reactivity  of erythrocytes  as demonstrated by an anti-I anti- 
body. 
In  striking  contrast,  antibodies  directed  against  the  core  structures  of Hs, 
such as structure 2 and 4 (see Fig.  1) reacted more strongly to fetal and/or cord 
erythrocytes than to adult erythrocytes (Fig. 2 A). The hemagglutination caused 
by these antibodies was extremely thermosensitive and completely disappeared 
at  37°C  (Fig.  2 B)  and  intensified  at  0-4°C  (Fig.  2 A).  The  agglutinability  of 
erythrocytes  by antibodies  directed  against  structure  2  and 4  was completely 
reversible between high and low temperatures.  There was a clear difference  of 
agglutinability between fetal, newborn,  and adult erythrocytes caused by anti- 
structure 4, 3, and 2 antibodies; however, this difference was not as remarkable 
as  the  agglutinability  caused  by  an  anti-structure  1  antibody  (see  Fig.  2A 
compared to 2 B).  Both adult and fetal  erythrocytes  intensified  their  reaction 
through protease treatment. 
In  using  the  antibodies  that  were  directed  against  structures  1,  2,  and  4, 
:omparisons were made between the complement fixation reaction ofglycolipids 
bhat were isolated from human intestinal  mucosa and glycolipids from human KIYOHIRO WATANABE  AND  SEN-ITIROH HAKOMORI  649 
TABLE IV 
Complement Fixing Reactivities of Glycolipids  Extracted from Normal and Colon 
Mueosa 
Case 1 
Normal  Cancer 
Case 2  Case 3  Case 4 
Normal  Cancer  Normal  Cancer  Normal  Cancer 
Reactivity with anti-structure 4  320  1280  160  640  320  1280  320  1280 
Reactivity with anti-structure 2  80  320  160  160  160  160  160  160 
Reactivity with anti-structure i  160  80  160  80  80  80  80  80 
(anti-H3) 
Complement  fixing reactivities of glycolipids extracted from normal colon mucosa and colon tumors with antibodies that are 
directed  against structure 1, 2, and 4 of  Fig. 3. Numbers are reciprocals  of  the dilution  of  antisera that could fix  complement by 1.2 
~g/50 ~I of  glycolipid antigen complexed with two times amount of lecithin  and cholesterol. 
colon carcinoma. The results of only four cases are shown in Table IV. A number 
of other cases were also determined (in total 16 cases). The average activity with 
anti-structure 4 antisera was 1:160 for normal mucosa tissue and 1:750 for cancer 
tissue,  respectively.  While the  antibody directed  against  structure  4  (Fig.  1) 
showed a remarkable differential reactivity between normal and tumor glycolip- 
ids, the antibodies directed against structure 1 and 2 showed a similar reactivity 
towards  normal  and  tumor  glycolipids.  Glycolipids  of several  cases  of colon 
carcinomas, as compared to normal mucosa tissue, were analyzed by thin-layer 
chromatography.  An  intensified  spot  corresponding  to  GlcNAcfll--*3Galfll--* 
4Glc/31-*lceramide  (structure  4)  was  observed in  glycolipid fraction  of colon 
carcinoma as compared to normal mucosa (see Fig. 3). 
Discussion 
The  results  clearly  indicate  that  highly  complex  variants  of blood  group 
glycolipids such as A c and H3 glycolipid are present in an appreciaole quantity 
in adult erythrocytes, but low in newborn and not in fetal erythrocyte mem- 
branes.  The low reactivity of fetal or newborn erythrocytes with anti-H3 anti- 
body was not enhanced by protease treatment.  This indicates that H3 structure 
was absent or very low in fetal or newborn erythrocytes rather than that  H~ 
structure  was  in  cryptic  state  in  fetal  or newborn  erythrocytes.  In  fact,  the 
concentration of A e structure, the branched analog of Hz in A erythrocytes, was 
significantly  low in  newborn  erythrocytes as compared to  adult erythrocytes 
through the surface-label procedure. 4 In striking contrast, the structures corre- 
sponding to the precursor of blood group glycolipids were detected by immuno- 
logical  reaction  in  appreciable  quantity  in  fetal  and  newborn  erythrocytes, 
whereas such reactions, due to the precursors, were less active in adult erythro- 
cytes. This is particularly remarkable for structure 4, i.e., the first aminosugar- 
containing  precursor  for  synthesizing  a  series  of compounds  which  lead  to 
various blood group chains, including the H3 structure. According to the defini- 
tion  (21) the property of the anti-H3 glycolipid behaves like that of the anti-I 
4 Similar experiments for determining  the chemical concentration of  A" and A n variants in fetal 
erythrocytes was unsuccessful because the quantity of fetal erythrocytes obtained from abortion 
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FIG.  3.  Neutral  glycolipid profile  of colon  mucosa  and  colon  carcinoma  by  thin-layer 
chromatography on Silica gel G with chloroform-methanol-water (60:35:8).  Neutral glyco- 
lipids were isolated from perchloric  acid extract  residue  of tissue  (see Text).  N:  normal 
mucosa, C: cancer tissue, 1, 2, 3, and 4 represent case numbers, R: reference glycolipid a, b, 
c,  d  are  lactosylceramide,  structure  4  (GlcNAc-*Gal-*Glc-*ceramide),  globoside,  and 
Forssman glycolipid, respectively. Y: yellow colored spot (nonglycolipid). 
antibody,  although  thermosensitivity  of hemagglutination  caused by anti-H3 
was not as remarkable as the thermosensitivity that was displayed by anti-I. 5 H3 
glycolipid inhibited I hemagglutination  (13) caused by anti-I (Ma) whose speci- 
ficity was directed  towards  B-Gall-,4/~-GlcNAcl-->6~Gal  (22),  and  the  same 
structure was found in H3 (13). The reaction of the antibodies that are directed 
against structures 2 and 4, is, by definition, similar to the reactivity of erythro- 
cytes displayed by anti-i,  and is characterized by thermosensitivity as well. 
The result of these studies suggests that step-by-step elongation and arboriza- 
tion of complex glycolipids, such as A c- and H3-carbohydrate chains, may take 
place during the development of human erythrocytes, but the exact correlation 
between the stage of development and the appearance of a definite structure in 
the red blood cell membranes  is not known and further  extensive studies are 
required. 
A remarkable difference between the reaction in glycolipids of human intes- 
tinal tumors and the reaction of normal intestinal mucosa was demonstrated by 
the antibody that was directed against structure 4. The difference in immuno- 
5 This reactivity is, however, probably due to anti-"branched H" rather than due to anti-I be- 
cause Marcus'  anti-H  (23) showed a  similar preferential  agglutination  of adult erythrocytes as 
well (Watanabe  and Hakomori,  unpublished  observation).  Furthermore,  "anti-H3" do not react 
with "I-glycoprotein without H" (observation by Dr. Ten Feizi, Medical Research Council, Middle- 
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logical reactivity of glycolipids may not always indicate the difference in chemi- 
cal quantity of glycolipids, as the immunologic reactivity of glycolipids can be 
modulated by the quality and the quantity of coexisting lipids and other glyco- 
lipids (12, 22). However, the differential reactivity ofglycolipids  between normal 
and tumor tissue was only observed through anti-structure 4 but not through 
other antibodies.  This suggested a  possibility that structure 4  is present in 
greater quantity in tumor tissue than in normal mucosal tissue.  Qualitative 
analysis of glycolipids of normal and tumor tissue through thin-layer chroma- 
tegraphy supported this possibility, i.e., an enhanced spot was observed corre- 
sponding to flGlcNAcl--*3flGall---~4BGlc-->ceramide. Since a  number of com- 
pounds could be  in the same position on thin-layer chromatography, further 
purification and identification of this compound is obviously needed. Further- 
more, immunofluorescent staining of frozen sections of various cases also sup- 
ported this possibility, i.e., some subpopulation of  colon tumor cells were stained 
strongly with anti-"structure 4" by indirect fluorescent method (Wang, S. M., T. 
Huang, K. Watanabe, and S. Hakomori, unpublished observation). An increase 
in human erythrocytes  ofa glycolipid with a structure similar to structure 4 was 
reported in a certain hereditary disease (24). In some cases, reaction against H3 
was slightly higher in normal tissue than in tumor tissue (see Table IV, last 
line, case 1 and 2). 
It is  plausible that  an  accumulation of structure 4,  (i.e.,  flGlcNAc(l~3)- 
flGal-~R  in  tumor tissue)  results  as  a  consequence of blocked or  inhibited 
synthesis of blood group chains. An analogous situation was reported in mam- 
mary carcinoma glycoprotein in which precursor structures for M and N deter- 
minants increased and were immunologically  detectable, whereas the M and N 
hapten were not significantly decreased. The precursor structures for M and N, 
which were present in human mammary  carcinoma, were identified as T and Tn 
antigen (25). A similar accumulation of precursor glycolipids, in relationship to 
a blocked synthesis of higher glycolipids, has been exemplified in many cases of 
transformed cell systems in vitro (26, 27). It has been clearly demonstrated in 
this study, however, that elongation and arborization of carbohydrate chains in 
human erythrocyte membranes are associated with ontogenetic development. 
On the other hand, the development of carbohydrate chains in gastrointestinal 
mucosa is modified or blocked by an accumulation of one of the precursors in 
intestinal tumors. 
The present study is, however, limited to adult, newborn fetal erythrocytes, 
colon mucosa, and colon tumors. Further extensive comparison of carbohydrate 
chains  in  various  tissues  and  their  correlation  to  ontogenesis is  obviously 
necessary. 
The change of a  carbohydrate chain length and the  state of arborization 
associated with the process of ontogenesis and oncogenesis may indicate that the 
structural complexity of a carbohydrate chain will influence membrane fluidity 
through altered interaction with proteins and other components of membranes. 
Summary 
Blood group ABH determinants in human erythrocytes are carried by four 
kinds ofglycolipid carbohydrate chains, differing in their structural complexity. 652  BLOOD GROUP CARBOHYDRATE CHAINS  IN  ONTOGENESIS 
They are A a, A b, A ¢', and A d for A variants, and HI, H2, H3, and H4 for H variants 
(Table I and Fig.  1).  Based on the surface labeling of A  variants and on the 
reactivity of erythrocytes to  antibodies  directed against  H3  and  against  its 
degradation products, it is concluded that complex variants of A or H determi- 
nants (A  t and Ad/or H3 and H4) are absent or significantly low in fetal erythro- 
cytes (80-150 days after gestation) and in newborn erythrocytes, whereas these 
complex structures are fully developed in adult erythrocytes. In contrast,  A 
determinants linked to simpler carbohydrate chains (A  a, A b variants) are fully 
developed before birth and do not show significant change after birth. 
The precursor of blood group carbohydrate chains seems to be abundant in 
fetal or newborn erythrocytes. This assumption is based on the higher reactivity 
of fetal or newborn erythrocytes to an antibody, which is directed against the 
precursor N-acetylglucosaminylfll-*3galactosylfll-,4glucosylceramide  than in 
adult erythrocytes. 
Reactions of glycolipids of gastrointestinal mucosa, with antibodies directed 
against H3 glycolipid and its degradation products, were compared to that of 
gastrointestinal tumors. The reaction to flGlcNAcl~3/3Gallo4Glc~ceramide 
(structure 4), which is the precursor of all blood group glycolipids, was consist- 
ently high in many cases of  tumor glycolipid than that of normal glycolipid. This 
as well as other evidence supports a general concept that the process of ontogen- 
esis of a blood group carbohydrate chain occurs as step-by-step elongation and 
arborization, and that blocking of such a development of a  carbohydrate chain 
occurs in the process of oncogenesis. 
Received for publication  9 April 1976. 
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